- Home
- CRGX vs SMBK Comparison
CRGX vs SMBK Comparison
Compare CRGX & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- SMBK
- Stock Information
- Founded
- CRGX 2021
- SMBK N/A
- Country
- CRGX United States
- SMBK United States
- Employees
- CRGX N/A
- SMBK N/A
- Industry
- CRGX
- SMBK Major Banks
- Sector
- CRGX
- SMBK Finance
- Exchange
- CRGX Nasdaq
- SMBK Nasdaq
- Market Cap
- CRGX 621.4M
- SMBK 575.5M
- IPO Year
- CRGX 2023
- SMBK N/A
- Fundamental
- Price
- CRGX $12.04
- SMBK $29.71
- Analyst Decision
- CRGX Strong Buy
- SMBK Buy
- Analyst Count
- CRGX 6
- SMBK 5
- Target Price
- CRGX $31.80
- SMBK $28.20
- AVG Volume (30 Days)
- CRGX 293.5K
- SMBK 54.2K
- Earning Date
- CRGX 11-12-2024
- SMBK 01-21-2025
- Dividend Yield
- CRGX N/A
- SMBK 1.09%
- EPS Growth
- CRGX N/A
- SMBK N/A
- EPS
- CRGX N/A
- SMBK 1.93
- Revenue
- CRGX N/A
- SMBK $159,196,000.00
- Revenue This Year
- CRGX N/A
- SMBK N/A
- Revenue Next Year
- CRGX N/A
- SMBK $12.16
- P/E Ratio
- CRGX N/A
- SMBK $15.21
- Revenue Growth
- CRGX N/A
- SMBK 2.18
- 52 Week Low
- CRGX $11.80
- SMBK $19.00
- 52 Week High
- CRGX $33.92
- SMBK $37.72
- Technical
- Relative Strength Index (RSI)
- CRGX 34.44
- SMBK 27.42
- Support Level
- CRGX $13.65
- SMBK $28.86
- Resistance Level
- CRGX $15.75
- SMBK $31.71
- Average True Range (ATR)
- CRGX 1.22
- SMBK 0.70
- MACD
- CRGX -0.03
- SMBK -0.13
- Stochastic Oscillator
- CRGX 5.83
- SMBK 27.69
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.